IP Library Granted Patent US 9,834,754
Granted Patent B2
US 9,834,754 · App. 14/359,517 · Granted Dec 5, 2017

Populations of hematopoietic progenitors and methods of enriching stem cells therefor

Inventors: Gordon Keller (Toronto, CA); Juan Carlos Zuniga-Pflucker (Toronto, CA); Marion J. Kennedy (Toronto, CA); Christopher Michael Sturgeon (Toronto, CA); Andrea Ditadi (Toronto, CA); Geneve Sheandra Awong (Toronto, CA)
Assignees: UNIVERSITY HEALTH NETWORK; SUNNYBROOK RESEARCH INSTITUTE
C12N5/0647G01N33/56972C12N2500/24C12N2500/35C12N2500/38C12N2501/105C12N2501/115C12N2501/125C12N2501/14C12N2501/145C12N2501/155C12N2501/16C12N2501/165C12N2501/2303C12N2501/2306C12N2501/2307C12N2501/2311C12N2501/26C12N2502/1394C12N2506/02C12N2506/45G01N2333/70596
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,834,754
App. No.
14/359,517
Granted
Dec 5, 2017
Kind
B2
Abstract

There is described herein a method of enriching a population of stem cells for hematopoietic progenitors. The method comprises inducing hematopoietic differentiation in a population of human embryonic stem cells or human induced pluripotent stem cells; sorting the population based on expression of CD43 and at least one of CD34, CD31 and CD144; and selecting a fraction that is at least one of CD34+CD43−, CD31+CD43− and CD144+CD43−. Also provided are populations of hematopoietic progenitors obtained by the methods described herein.

Claims (18)

1. A method of enriching a population of stem cells for hematopoietic progenitors from a population of human pluripotent stem cells that have been induced to undergo hematopoietic differentiation, the method comprising:

a. inducing hematopoietic differentiation in a population of human pluripotent stem cells, wherein activin/nodal signaling is inhibited between day 1 and day 4 of differentiation;

b. sorting the induced population based on expression of CD34 and CD43; and

c. selecting a fraction of the cell population that is CD34 + CD43 − , and

wherein the sorting and cell fraction selection is performed on a day selected from about day 6 to about day 11 of differentiation.

2. The method of claim 1 , wherein inducing hematopoietic differentiation is conducted serum free.

3. The method of claim 1 , wherein inducing hematopoietic differentiation is conducted stroma free.

4. The method of claim 1 , wherein inducing hematopoietic differentiation comprises culturing the population with BMP4.

5. The method of claim 1 , wherein inducing hematopoietic differentiation comprises culturing the population with bFGF.

6. The method of claim 1 , wherein inducing hematopoietic differentiation comprises culturing the population with at least one of VEGF, DKK, IL-6 and IL-11, and/or combinations thereof, between days 3 and 11, or between days 4 and 9.

7. The method of claim 1 , wherein inducing hematopoietic differentiation comprises culturing the population with at least one of SCF and EPO, between days 4 and 11, or between days 6 and 9.

8. The method of claim 1 , wherein inducing hematopoietic differentiation comprises culturing the population with at least one of TPO, Flt-3 and IL-3, and/or combinations thereof, between days 6 and 11, or and 8 and 9.

9. The method of claim 1 , wherein inhibiting activin/nodal signaling comprises culturing the population with an activin/nodal inhibitor.

10. The method of claim 9 , wherein the inhibitor is SB-431542.

11. The method of claim 1 , wherein the fraction comprises at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% hematopoietic progenitors.

12. The method of claim 10 , wherein the population is cultured with between 1 μM to 10 mM, 1 μM to 1 mM, or about 6 μM SB-431542.

13. The method of claim 1 , wherein activin/nodal signaling is inhibited between day 2 and day 4 of differentiation.

14. The method of claim 13 , wherein activin/nodal signaling is inhibited by culturing the population is cultured with between 1 μM to 10 mM, 1 μM to 1 mM, or about 6 μM SB-431542.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2014
From: KELLER, GORDON; KENNEDY, MARION J.; STURGEON, CHRISTOPHER MICHAEL; DITADI, ANDREA
To: UNIVERSITY HEALTH NETWORK
Reel/Frame 033791/0494 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2014
From: ZUNIGA-PFLUCKER, JUAN CARLOS; AWONG, GENEVE SHEANDRA
To: SUNNYBROOK RESEARCH INSTITUTE
Reel/Frame 033791/0527 →
Continuity (2)
Provisional Application 61562094 · Nov 21, 2011
Related Publication 20140322808A1 · Oct 30, 2014